Evidence map›Paper›PMID 37035299›Full record

ArticleFrontiers in medicine2023

Sacral neuromodulation remote programming in patients with refractory lower urinary tract dysfunction: China's experience during the COVID-19 pandemic.

Lingfeng Meng, Huimin Hou, Peng Zhang, Yinjun Gu, Benkang Shi, Yan Li, Qingwei Wang, Yifei Zhang, Lijuan Ren, Qi Chen and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lingfeng MengDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Huimin HouDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Peng ZhangDepartment of Urology, Beijing Chaoyang Hospital, Institute of Urology, Capital Medical University, Beijing, China.
Yinjun GuDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China.
Benkang ShiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yan LiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Qingwei WangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yifei ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Lijuan RenDepartment of Urology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Qi ChenDepartment of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhen YuanDepartment of Urology, Fuyang People's Hospital, Fuyang, China.
Fan GuoDepartment of Urology, Hubei Provincial Hospital of TCM, Wuhan, China.
Dianyou LiDepartment of Neurosurgery, Ruijin Hospital, Medical College, Shanghai Jiaotong University, Shanghai, China.
Yunfu MaDepartment of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Sheng DongDepartment of Neurosurgery, Beijing Tsinghua Changgung Hospital, Beijing, China.
Zhijun LiuDepartment of Urology, Qingdao Municipal Hospital, Qingdao, China.
Aijia ShangDepartment of Neurosurgery, Chinese PLA General Hospital, Beijing, China.
Bo LiDepartment of Urology, Shandong Provincial Hospital, Jinan, China.
Wei XuDepartment of Urology, Zoucheng People's Hospital, Zoucheng, China.
Jianwei LvDepartment of Urology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
Yaoguang ZhangDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Sacral neuromodulation is an effective, minimally invasive treatment for refractory lower urinary tract dysfunction. However, regular postoperative programming is crucial for the maintenance of the curative effects of electronic sacral stimulator devices. The outbreak of coronavirus disease 2019 (COVID-19) limited the ability of practitioners to perform traditional face-to-face programming of these stimulators. Therefore, this study aimed to evaluate the application of remote programming technology for sacral neuromodulation during the COVID-19 pandemic in China. Materials and methods: We retrospectively collected data including baseline and programming information of all patients with lower urinary tract dysfunction who underwent sacral neuromodulation remote programming in China after the outbreak of COVID-19 (i.e., December 2019). The patients also completed a self-designed telephone questionnaire on the subject. Results: A total of 51 patients from 16 centers were included. They underwent 180 total remote programming visits, and 118, 2, 25, and 54 voltage, current, pulse width, and frequency adjustments, respectively, were performed. Additionally, remote switching on and off was performed 8 times; impedance test, 54 times; and stimulation contact replacement, 25 times. The demand for remote programming was the highest during the first 6 months of sacral neuromodulation (average, 2.39 times per person). In total, 36 out of the 51 patients completed the questionnaire survey. Of these, all indicated that they chose remote programming to minimize unnecessary travel because they had been affected by COVID-19. The questionnaire also showed that remote programming could reduce the number of patient visits to the hospital, save time, reduce financial costs, and would be easy for patients to master. All surveyed patients indicated that they were satisfied with remote programming and were willing to recommend it to other patients. Conclusion: Remote programming for sacral neuromodulation is feasible, effective, safe, and highly recommended by patients with refractory lower urinary tract dysfunction. Remote programming technology has great development and application potential in the post-pandemic era.

Indexed as

COVID-19lower urinary tract dysfunctionremote programmingsacral neuromodulationurinary bladder

Identifiers

PMID37035299
PMCPMC10081490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.